Short answer
Neurocrine Biosciences Inc (NBIX) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results announced for quarter ended September 30, 2026.
Neurocrine Biosciences Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results announced for quarter ended September 30, 2026
- Full financial results and management commentary provided in Exhibit 99.1
- Investor focus: quarterly performance, guidance, and pipeline updates in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1.123B, up 41% year over year, with net product sales exceeding $1B for the first time
- INGREZZA sales $801M, up 17%; 2026 guidance raised to $2.9B-$2.925B
- CRENESSITY sales $211M, up from $98M; approximately 80% reimbursement supports continued launch momentum
- VYKAT XR contributed $107M, validating the Soleno acquisition while adding $2.2B of intangible assets and $35M quarterly amortization
- Non-GAAP EPS $3.29 versus $2.17, while GAAP EPS fell to $1.96 from $2.04 amid acquisition costs and a $52M investment loss
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Neurocrine Biosciences Inc 8-K filings
Get the next NBIX 8-K as it lands
Follow NBIX for push alerts, or ask the research agent what this filing means.